AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06710678 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Study Break
Description: A 10-minute walking/upper extremity light movement indoor break from study session
Study NCT06710678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Study Break
Description: Participants will engage in social media use/engagement during a 10-minute study session break
Study NCT06707181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: • The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalaf
Description: • The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalafil 5 mg (Group C) and tamsulosin 0.4 mg plus tadalafil 5 mg (Group D). Drugs are given for a maximal duration of 28 days.
Study NCT06708273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint induced movement therapy
Description: Constraint the sound side and encourage movement of the burned side
Study NCT06708273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positioning - stretching
Description: Position hand in functional hand position - stretching against deformity position
Study NCT06708273 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positioning - stretching
Description: Position hand in functional hand position - stretching against deformity position
Study NCT06708273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: constraint induced movement therapy
Description: constraining sound hand to enforce patient to use affected burned dominant hand
Study NCT06726577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP04HN106
Description: During the treatment period, the experimental drug group received intravenous injections of 0.83mL/kg TP04HN106 each time; During the extension period, all subjects received intravenous injection of 0.83mL/kg TP04HN106.
Study NCT05787574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emapalumab
Description: Emapalumab on Days -22 (22 days before the day of the stem cell transplant), -15, -8, and -1.
Study NCT05787574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine and Dexamethasone
Description: Fludarabine and dexamethasone for 5 days in a row on Days -22 through -18.
Study NCT05787574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Participants in both groups will receive their standard-of-care stem cell transplant on Day 0.
Study NCT06085833 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nanomechanical Phenotype Test
Description: The ARTIDIS ART-1 device is an in-vitro diagnostic device based on Atomic Force Microscope (AFM) technology. The ART-1 device uses a probe to measure the nanomechanical phenotype of tissue components. ARTIDIS nanomechanical phenotype measurements are performed on fresh tissue after it is collected via biopsy or resection.
Study NCT06577857 — intervention group
Intervention type: DEVICE
Intervention: Inferonasal Minimally Invasive Micro Sclerostomy
Description: The Inferonasal MIMS® procedure uses the proprietary MIMS® device, which creates a sclerostomy in the inferonasal quadrant of the eye.
Study NCT05876585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg ampoule
Description: Study drug
Study NCT05876585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide 10 mg ampoule
Description: Comparator drug
Study NCT04761393 — intervention group
Intervention type: PROCEDURE
Intervention: Hyperpolarized 129Xe (Xenon) diffusion-weighted MRI
Description: Participants will inhale a one litre gas mixture containing hyperpolarized 129Xe mixed with nitrogen (N2) or helium (4He) from a one litre dose bag. Breath-hold will be up to 16 seconds
Study NCT06726577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The placebo group received intravenous injections of 0.83mL/kg of saline each time. In the experiment, all subjects received Liraglutide tablets as the standard baseline treatment.
Study NCT06742320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma education
Description: There are very few studies examining the asthma knowledge level, quality of life and asthma control of children in Turkey.
Study NCT06744400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grafalon® administered during 5 consecutive days at 2 mg/kg/j
Description: This de-escalation study was planned to investigate 3 doses level of Grafalon® administered during 5 consecutive days, i.e.:~Group 3 : 2 mg/kg/j, Group 2 : 1 mg/kg/j, Group 1 : 0,5 mg/kg/j.~Group 3 receives treatment in accordance with health recommendations as part of prophylactic treatment for acute rejection after allogeneic solid organ transplantation, at the minimum dose, i.e., 2 to 5 mg/kg/day for 5 to 21 days.
Study NCT06744400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grafalon® administered during 5 consecutive days at 1 mg/kg/j
Description: This de-escalation study was planned to investigate 3 doses level of Grafalon® administered during 5 consecutive days, i.e.:~Group 3 : 2 mg/kg/j, Group 2 : 1 mg/kg/j, Group 1 : 0,5 mg/kg/j.~Group 2 receive treatment at lower doses than the recommended dose for the same duration (5 days). Treatment begins on the day of transplantation immediately before the procedure at induction of sedation.
Study NCT06744400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grafalon® administered during 5 consecutive days at 0,5 mg/kg/j
Description: This de-escalation study was planned to investigate 3 doses level of Grafalon® administered during 5 consecutive days, i.e.:~Group 3 : 2 mg/kg/j, Group 2 : 1 mg/kg/j, Group 1 : 0,5 mg/kg/j.~Group 1 receive treatment at lower doses than the recommended dose for the same duration (5 days). Treatment begins on the day of transplantation immediately before the procedure at induction of sedation
Study NCT06737016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Children will be maintained on an oral dose of Tamsulosin 0.1 mg once daily (in children aged less than 2 years old) and 0.2 mg once daily (≥2 years old).
Study NCT06737016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin
Description: Children will be maintained on an oral dose of Oxybutynin 0.2 mg/kg 2 times daily.
Study NCT06737016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: Children will be maintained on an oral dose of Oxybutynin 0.2 mg/kg 2 times daily.
Study NCT06737016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMZ)
Description: Children will be maintained on an oral prophylactic dose of Trimethoprim/sulfamethoxazole 2 mg/kg single dose at night.
Study NCT06737016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMZ)
Description: Children will be maintained on an oral prophylactic dose of Trimethoprim/sulfamethoxazole 2 mg/kg single dose at night.
Study NCT06744452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: harmony
Description: Use of the app-based digital self-help intervention harmony over a 12-week-period. The app was designed for stress management and the preventive promotion of mental health. Harmony provides users with access to a wide range of psychological self-help content, including video episodes, audio sessions, texts, and downloadable materials. Utilizing artificial intelligence, Harmony offers personalized content suggestions tailored to the user's individual situation and preferences, ensuring the content remains relevant and updated. Content is delivered through a combination of psychoeducation, guided exercises, relaxation techniques, meditations, practical tasks, self-reflection activities, and everyday application tasks.
Study NCT06744803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamified Neuropathy Management Application on Cancer Behavior
Description: The study will be conducted in three phases:~Phase 1: The content of the gamified neuropathy management application used in the study will be prepared by the researchers using relevant literature.~Phase 2: The developed gamified neuropathy management application will be introduced to patients during one-on-one interviews at the daytime chemotherapy clinic. After collecting pre-test data, the application will be sent to the patients, who will be asked to use it for 8 weeks.~Phase 3: Following the start of the study's implementation, patients will be contacted in the 4th and 8th weeks to collect mid-study and post-test data.
Study NCT06108323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Theapeutic exercise plus action observation training
Description: Participants make an observation of actions related to the training they are going to perform. Subsequently, they perform the therapeutic exercise session.
Study NCT06108323 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Therapeutic exercise plus sham observation training
Description: Participants make a sham observation. Subsequently, they perform the therapeutic exercise session.
Study NCT05485727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Balance Exercises , Gait training, Trunk control, Range of motion exercises for lower limbs
Study NCT05485727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy
Description: Balance Exercises , Gait training, Trunk control, Range of motion exercises for lower limbs
Study NCT06743789 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Group 1 (3 participants) - will receive a dose of 20 Gy (Gray, a measurement of radiation) in a single study intervention (one study intervention day)
Study NCT06743789 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Group 2 (3 participants) - will receive a dose of 15 Gy in a single study intervention (one study intervention day)
Study NCT06743789 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Group 3 (3 participants) - will receive a dose of 10 Gy in a single study intervention (one study intervention day)
Study NCT05419505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCH-aaes
Description: Administered by subcutaneous injection.
Study NCT06743789 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Group 1 (3 participants) - will receive a dose of 12 Gy given over 3 days (Days 1, 2 and 3). (Total radiation dose = 36Gy)
Study NCT06743789 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Group 2 (3 participants) - will receive a dose of 10 Gy given over 3 days (Days 1, 2 and 3). (Total radiation dose = 30Gy)
Study NCT06743789 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Group 3 (3 participants) - will receive a dose of 8 Gy given over 3 days (Days 1, 2 and 3). (Total radiation dose = 24Gy)
Study NCT06745167 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed field ablation
Description: Utilizing pulsed field ablation (PFA), combining pulmonary vein isolation (PVI) with extensive ablation based on anatomical landmarks (including posterior wall box isolation) and electrogram-guided ablation.
Study NCT06745167 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation alone
Description: Using conventional radiofrequency ablation technology, combines pulmonary vein isolation (PVI) with extensive ablation based on anatomical landmarks (including posterior wall box isolation) and electrogram-guided ablation
Study NCT06745206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyophilized Recombinant Human Brain Natriuretic Peptide
Description: Prior to rh-BNP administration, measure: PiCCO indices, hemodynamic parameters, venous return, tissue perfusion, echocardiographic parameters, ultrasound indices, 2-hour averaged urine output and fluid balance. Repeat all above-mentioned measurements at 30 minutes post-initiation.
Study NCT06744686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-102
Description: 50mg, 150mg, 300mg, 600mg
Study NCT06744686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-102
Description: 50mg, 150mg, 300mg
Study NCT06744686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT06743568 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transcatheter aortic valve replacement
Description: Eligible patients will be randomized 1:1 to self-expandable valve group or balloon-expandable valve group.
Study NCT06743555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation without surgery
Description: Patients randomized to this arm will forego standard-of-care thoracic surgery and will undergo strict surveillance based on serial radiological follow-up and ctDNA monitoring
Study NCT06743555 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care surgery
Description: Patients randomized to this arm will undergo standard-of-care thoracic surgery and undergo post-operative surveillance with serial radiological follow-up and ctDNA monitoring
Study NCT06744010 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sub sartorial canal block and popliteal block in ankle surgeries
Description: All patients will be anesthetized with PNBs for surgery.~* PNBs will be performed in a block room at least 30minute preoperatively.~* All PNBs will be performed under ultrasound guidance (LOGIQ P6, GE Healthcare; Chicago, IL) using a high-frequency linear transducer (3.4-10.8MHz).~* All blocks will be performed after skin preparation with 2% chlorhexidine gluconate by 1 orthopedic surgeon (YUP) with vast experience in ultrasound-guided nerve block techniques.~* A 22-ga Tuohy needle will be introduced in-plane and 2 to 3mL of saline will be used to confirm the correct position of the needle tip near the target nerve.~* The study medication will be administered through the needle as a bolus of 20mL of a 1:1 mixed solution of bupivacaine 0.75% and lidocaine 1%.~* The total volume per every block will be 20 ml in the form of bupivacaine 1.25% with 1:200,000 epinephrine and 250 mg Mgso4.
Study NCT06744010 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: femoral block and popliteal block in ankle surgeries
Description: * All patients will be anesthetized with PNBs for surgery.~* PNBs will be performed in a block room at least 30minute preoperatively.~* All PNBs will be performed under ultrasound guidance (LOGIQ P6, GE Healthcare; Chicago, IL) using a high-frequency linear transducer (3.4-10.8MHz).~* All blocks will be performed after skin preparation with 2% chlorhexidine gluconate by 1 orthopedic surgeon (YUP) with vast experience in ultrasound-guided nerve block techniques.~* A 22-ga Tuohy needle will be introduced in-plane and 2 to 3mL of saline will be used to confirm the correct position of the needle tip near the target nerve.~* The study medication will be administered through the needle as a bolus of 20mL of a 1:1 mixed solution of bupivacaine 0.75% and lidocaine 1%.~* The total volume per every block will be 20 ml in the form of bupivacaine 1.25% with 1:200,000 epinephrine and 250 mg Mgso4.
Study NCT06735950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volunteering in Place Program
Description: Implementation of the VIP Program consists of 4 steps guided by the Social Ecological Model (SEM) with Interpersonal interventions guided by Social Cognitive Theory (SCT), and will be implemented over a 6-month period by research supported Volunteer Coordinators. The four steps of the VIP Program are: Step 1: Stakeholder Team, Staff and Family Education; Step 2: Assessment of AL Environment and Residents Abilities and Interests; Step 3: Ongoing Implementation of the Volunteer Plan; and Step 4: Reassessment of the Volunteer Activity. Participants will volunteer three time per week for approximately 30 minutes.
Study NCT06735950 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recreational activity
Description: The Recreational Activities group intervention will consist of similar staff education regarding the benefits of engaging residents in meaningful activities as described in Step 1 above, without other steps associated with the VIP Program. The Recreational Activities group will be exposed to a research team RA coordinator who will provide a current events activity (reviewing the daily newspaper) for the participants in the RA group three times per week for approximately 30 minutes as an attention control.
Study NCT06745466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganirelix acetate
Description: Ganirelix acetate (Antagon) will be used to prevent endogenous production of ovarian hormones in young women. Ganirelix is derived from native GnRH, and acts by competitively blocking GnRH receptors on the pituitary and subsequent pathways. Thus, administration of the GnRH antagonist (GnRHant) suppresses steroidogenesis, leading to low or undetectable serum estrogen and progesterone concentrations, which occurs within two days of initiation of administration. Women will self-administer subcutaneous injections (0.25 mg/day in 0.5 ml of normal saline) of the GnRH antagonist ganirelix acetate (Antagon, Organon, Inc., West Orange, New Jersey,) every day for \~12-15 days (starting on day \~2-4 of the menstrual cycle). Testing will occur on day 3-4 and day14-15 of using Antagon.
Study NCT06744712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Testing
Description: Pharmacogenomic testing will be completed by the vendor. The vendor is certified under CLIA-88 and accredited by the College of American Pathologists as qualified to perform high-complexity testing. Genomic DNA extracted from the swab will be analyzed by PCR using Thermo Fisher TaqMan® and/or LGC Biosearch BHQ® probe-based methods to interrogate the variant locations listed in (See Appendix II). Twenty-seven genes are evaluated and reported.
Study NCT06745245 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional counseling and supplementation with a gelatin with prebiotic fiber and probiotic microorganisms
Description: One serving (15 g) of symbiotic gelatin
Study NCT04567615 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT04567615 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days
Study NCT04764357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paxman Scalp Cooling System
Description: Scalp cooling will begin at least 30-45 minutes prior to administration of each chemotherapy (45 minutes for those with thick or coarse hair types). Scalp temperature will be maintained at +3°C (37°F) throughout drug administration and for at least 120-180 minutes after discontinuing the infusion. Scalp cooling will occur with each dose of chemotherapy.
Study NCT04764357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alopecia Assessments
Description: Photographs will be taken prior to the use of the scalp cooling system and once at the end of the study. Patients with solid tumors will have additional photographs taken after every 2 cycles of chemotherapy.
Study NCT04764357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Reported Outcomes Questionnaires
Description: * Selected questions from NCI PRO-CTCAE™, Chemotherapy-Induced Alopecia Distress Scale (CADS), and PediQUEST Memorial Symptom Assessment Scale, at the following time points: baseline, after every 2 cycles of chemotherapy, 4 week follow up and end of study.~* Tolerability Questionnaire each time the cooling cap is used and at the end of study
Study NCT04921306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clenbuterol Hydrochloride
Description: Daily ingestion of clenbuterol hydrochloride capsules (40 microgram/day) for a total period of 28 days with a wash-out period of at least 6-8 weeks.
Study NCT04921306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily ingestion of placebo capsules for a total period of 28 days with a wash-out period of at least 6-8 weeks.
Study NCT05856942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health service - home-based PrEP monitoring
Description: Home-based PrEP care
Study NCT05269797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led health coaching re: heart failure self-care management
Description: A focus group meeting will be arranged with the nurse participants to provide training on the study intervention specific to the Nurse-led health coaching intervention. The intervention involves identifying barriers and finding strategies and solutions to self-care management, while employing a self-care HF management tool of adjusting diuretic dosing (ADD) according to the congestive cardiac calendar (designed in collaboration with nurses in Phase 1). It will be essential for the nurses to document key information pertaining to the rationale for these decision-making strategies or solutions. This is in comparison to the standard of care in primary health care of nurses not taking a standardize approach towards health coaching and the patient being instructed by the practitioner to take a set diuretic dosing (SDD).
Study NCT05645887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human albumin
Description: Human albumin from day 0 to 7 if serum albumin concentrations \<35g/l.
Study NCT05645887 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Saline solution from day 0 to day 7.
Study NCT04985682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADVATE
Description: Antihemophilic factor (AHF) activity expressed in international units (IU) per vial.